Impact of trichostatin A and sodium valproate treatment on post-stroke neurogenesis and behavioral outcomes in immature mice

No real clue on what this means so go ask your researcher or great stroke association.
http://www.frontiersin.org/cellular_neuroscience/10.3389/fncel.2013.00123/full?

Shanu George¹, Shilpa D. Kadam^1,2,3, Natasha D. Irving¹, Geoffrey J. Markowitz¹, Saba Raja¹, Anthony Kwan¹, YuShan Tu¹, Huigen Chen¹, Charles Rohde⁴, Dani R. Smith⁵ and Anne M. Comi^1,3,6*

• ¹Department of Neurology and Developmental Medicine, Hugo Moser Kennedy Krieger Research Institute, Baltimore, MD, USA
• ²Neuroscience, Kennedy Krieger Institute, Baltimore, MD, USA
• ³Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA
• ⁴Department of Biostatistics, Johns Hopkins School of Public Health, Baltimore, MD, USA
• ⁵Neurogenetics and Behavior Center, Department of Psychological and Brain Sciences, Johns Hopkins University, Baltimore, MD, USA
• ⁶Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, MD, USA

Stroke in the neonatal brain frequently results in neurologic impairments including cognitive disability. We investigated the effect of long-term sodium valproate (valproate) and trichostatin A (TSA) treatment upon post-stroke neurogenesis in the dentate gyrus (DG) of stroke-injured immature mice. Decreased or abnormal integration of newborn DG neurons into hippocampal circuits can result in impaired visual-spatial function, abnormal modulation of mood-related behaviors, and the development of post-stroke epilepsy. Unilateral carotid ligation of P12 CD1 mice was followed by treatment with valproate, TSA, or vehicle for 2 weeks, bromodeoxyuridine (BrdU) administration for measurement of neurogenesis, and perfusion at P42 or P60. Behavior testing was conducted from P38–42. No detrimental effects on behavior testing were noted with TSA treatment, but mildly impaired cognitive function was noted with valproate-treated injured animals compared to normal animals. Significant increases in DG neurogenesis with both TSA and valproate treatment were noted with later administration of BrdU. Increased mortality and impaired weight gain was noted in the valproate-treated ligated animals, but not in the TSA-treated animals. In summary, the impact of histone deacetylase (HDAC) inhibition upon post-stroke subgranular zone neurogenesis is likely to depend on the age of the animal at the time point when neurogenesis is assessed, duration of HDAC inhibition before BrdU labeling, and/or the stage in the evolution of the injury.